Merck & Co. (NASDAQ:MRK) extended its bullish run into a seventh straight session, with shares trading 1.56% higher at ...

Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Shares of Merck & Co. Inc. MRK rose 1.82% to $121.93 Friday, on what proved to be an all-around great trading session for the ...

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...

In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO ...

MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches ...

Merck topped Q4 earnings and revenue estimates, helped by Keytruda and animal health growth, but its 2026 earnings and sales guidance came in below Wall Street expectations.

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.

By Michael Erman and Mariam Sunny Feb 3 (Reuters) - Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates, saying the imminent loss of exclusivity on diabetes drug Januvia ...

Merck & Co. is no longer in talks to acquire biotech firm Revolution Medicines Inc. after the two companies couldn’t agree on ...

Merck & Co forecast 2026 sales and profit that missed Wall Street’s expectations as continued challenges with its HPV vaccine ...

It was revealed in a recent SEC filing that Chirfi Guindo, Chief Marketing Officer at Merck & Co (NYSE: MRK) made a ...